S100A7在基底细胞样乳腺癌中的表达及临床意义

doi:10.3760/cma.j.issn.1673422X.2014.03.022

摘要/Abstract

摘要： 目的检测S100A7蛋白和CD34蛋白在基底细胞样乳腺癌中的表达情况，分析S100A7与基底细胞样乳腺癌临床病理特征之间的关系及其与CD34标记的微血管密度（MVD）值之间的关系，探讨S100A7在基底细胞样乳腺癌血管生成和侵袭转移中的作用。方法采用免疫组织化学二步法检测60例基底细胞样乳腺癌、40例非基底细胞样乳腺癌、20例正常乳腺组织中S100A7和CD34的表达情况。结果S100A7在基底细胞样乳腺癌、非基底细胞样乳腺癌及正常乳腺组织中的表达率分别为83.33%、62.50%、35.00%，差异有统计学意义（χ2=5.556，P＜0.05； χ2=17.107，P＜0.05； χ2=4.051，P＜0.05）。S100A7与基底细胞样乳腺癌患者的淋巴结转移、TNM分期及MVD值呈正相关，而与患者的年龄、肿瘤大小无明显相关性。结论S100A7的表达上调可能与基底细胞样乳腺癌的发生发展、侵袭转移及血管形成过程有关。S100A7促进血管的生成的作用可能是其促进肿瘤的局部侵袭和远处转移的重要因素。

关键词: S100蛋白质类, 癌,基底细胞, 乳腺肿瘤, 新生血管化,病理性

Abstract: ObjectiveTo detect the protein expressions of S100A7 and CD34 in basallike breast carcinoma and analyze the clinical relationship between S100A7 and basallike breast cancer and the connection with CD34 markers microvessel denisity (MVD). To study the function of S100A7 in basallike breast cancer angiogenesis, invasion and metastasis. MethodsImmunohistochemistry (IHC) was used to detect the expressions of S100A7 and CD34 in 60 cases of basallike breast cancer, 40 cases of non basallike breast cancer and 20 cases of normal breast tissues. ResultsThe expressions of S100A7 in basallike breast cancer, non basallike breast cancer and normal breast tissues were 83.33%, 62.50% and 35.00% respectively. There were significant differences among them (χ2=5.556, P＜0.05l; χ2=17.107, P＜0.05; χ2=4.051, P＜0.05). There was positive correlation between S100A7 and lymph node metastasis, TNM staging and MVD of basallike breast cancer patients. But there was no significant correlation between S100A7 and patient′s age and tumor sizes. ConclusionThe upregulation of S100A7 expressions may be associated with the occurrence and development, invasion and metastasis, angiogenesis of basallike breast cancer. The effects of S100A7 promoting angiogenesis may be an important factor in the acceleration of the local invasion and distant metastasis in basallike breast cancer.

Key words: S100 proteins, Carcinoma, basal cell, Breast neoplasms, Neovascularization, pathologic

姜丽, 赵文明, 孙吉瑞, 周炳娟, 张金库. S100A7在基底细胞样乳腺癌中的表达及临床意义[J]. 国际肿瘤学杂志, 2014, 41(3): 229-232.

JIANG Li, ZHAO Wen-Ming, SUN Ji-Rui, ZHOU Bing-Juan, ZHANG Jin-Ku. Expression of S100A7 in basal-like breast carcinoma and its clinical significance[J]. Journal of International Oncology, 2014, 41(3): 229-232.

参考文献

［1］ Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basallike subtype of invasive breast carcinoma［J］. Mod Pathol, 2006, 19(2):264271. ［2］ Savage K, Leung S, Todd SK, et al. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis［J］. Breast Cancer Res Treat, 2008, 110(2):245256. ［3］ Banerjee AG, Bhattacharyya I, Vishwanatha JK. Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia［J］. Mol Cancer Ther, 2005, 4(6):865875. ［4］ Krop I, Mrz A, Carlsson H, et al. A putative role for psoriasin in breast tumor progression［J］. Cancer Res, 2005, 65(24):1132611334. ［5］ Emberley ED, Niu Y, Curtis L, et al. The S100A7cJun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer［J］. Cancer Res, 2005, 65(13):56965702 ［6］ Paruchuri V, Prasad A, McHugh K, et al. S100A7downregulation inhibits epidermal growth factorinduced signaling in breast cancer cells and blocks osteoclast formation［J］. PLoS One, 2008, 3(3):e1741. ［7］ West NR, Watson PH. S100A7 (psoriasin) is induced by the proinflamatory cytokines on costatinM and interleukin6 in human breast cancer［J］. Oncogene, 2010, 29(14):20832092. ［8］ Meyer JS, Alvarez C, Milikowski C, et al .Breast carcinoma malignancy grading by BloomRichardson system vs proliferation index: reproducibility of grade and advantages of proliferation index［J］. Mod Pathol, 2005, 18(8):10671078. ［9］ Mbius C, Demuth C, Aigner T et al. Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma［J］. Eur J Surg Oncol, 2007, 33(8):10251029. ［10］ Ruse M, Lambert A, Robinson N, et al. S100A7, S100A10, and S100A11 are transglutaminase substrates［J］. Biochemistry, 2001, 40(10):31673173. ［11］ Madsen P, Rasmussen HH, Leffers H, et al. Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly upregulated in psoriatic skin［J］. J Invest Dermatol， 1991， 97(4):701712. ［12］ Jinquan T, Vorum H, Larsen CG, et al. Psoriasin: a novel chemotactic protein［J］. J Invest Dermatol, 1996, 107(1):510. ［13］ Celis JE, Rasmussen HH, Vorum H, et al. Bladder squamous cell carcinomas express psoriasin and externalize it to the urine［J］. J Urol, 1996, 155(6):21052112. ［14］ AlHaddad S, Zhang Z, Leygue E, et al. Psoriasin (S100A7) expression and invasive breast cancer［J］. Am J Pathol, 1999, 155(6):20572066. ［15］ Luu HH, Zhou L, Haydon RC, et al. Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma［J］. Cancer Lett, 2005, 229(1):135148.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[14]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.
[15]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.